FDA Brief

Warning letters Drugs

FDA warning letter to

Naturista Store LLC

High riskIssued Mar 26, 2025Posted Apr 15, 2025Center for Drug Evaluation and Research (CDER)

Naturista Store sold ADVANCE KING, labeled a supplement, containing undeclared dexamethasone, diclofenac, and methocarbamol; FDA calls it an unapproved, misbranded drug.

What happened

FDA reviewed https://naturistastore.com/ from Dec 2024 to February 2025 and obtained a sample of “ADVANCE KING,” which the website offered for sale in the United States. Laboratory analysis found the product contained undeclared dexamethasone, diclofenac, and methocarbamol. The product was labeled as a dietary supplement but marketed with claims to relieve pain and treat conditions such as sciatica, osteoarthritis, and gout.

What FDA found

  1. The product’s labeling does not disclose that it contains dexamethasone, diclofenac, and methocarbamol.

    FD&C Act §502(a), 21 U.S.C. 352(a); §201(n), 21 U.S.C. 321(n)
  2. The product is an unapproved new drug sold in interstate commerce without an FDA-approved application.

    FD&C Act §§505(a), 301(d), 21 U.S.C. 355(a), 331(d)
  3. The product is a drug because its labeling claims it treats pain, sciatica, osteoarthritis, gout, and other conditions.

    FD&C Act §201(g)(1)(B), 21 U.S.C. 321(g)(1)(B)
  4. The product is excluded from being a dietary supplement because it contains diclofenac and dexamethasone, which were approved as drugs before being marketed as supplements or food.

    FD&C Act §201(ff)(3)(B)(i), 21 U.S.C. 321(ff)(3)(B)(i)
  5. Labeling presents ADVANCE KING as a natural supplement while concealing active drug ingredients, making it misleading.

    FD&C Act §502(a), 21 U.S.C. 352(a)

What FDA wants

FDA asks Naturista Store to notify it in writing within 15 working days of the steps taken to correct the violations, prevent recurrence, and include supporting documents. If corrective action cannot be completed in that time, the company must state why and give a completion date.

Who should pay attention

  • online retailers selling imported arthritis or pain supplements
  • brands and distributors of NatuMex, Artri King, Royal Honey, or similar supplements
  • consumers who bought ADVANCE KING or similar products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk